Simplify Asset Management Inc. Cuts Stock Position in Sanofi (NASDAQ:SNY)

Simplify Asset Management Inc. decreased its holdings in shares of Sanofi (NASDAQ:SNY) by 80.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,387 shares of the company’s stock after selling 163,756 shares during the period. Simplify Asset Management Inc.’s holdings in Sanofi were worth $1,948,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Guardian Partners Inc. purchased a new position in Sanofi during the fourth quarter valued at $9,162,000. Sei Investments Co. raised its position in shares of Sanofi by 8.0% during the 4th quarter. Sei Investments Co. now owns 644,302 shares of the company’s stock worth $31,075,000 after purchasing an additional 47,801 shares during the last quarter. American Century Companies Inc. lifted its stake in Sanofi by 1.8% in the 4th quarter. American Century Companies Inc. now owns 1,707,057 shares of the company’s stock valued at $82,331,000 after buying an additional 29,536 shares in the last quarter. Lee Danner & Bass Inc. acquired a new stake in Sanofi in the 4th quarter worth about $31,000. Finally, DCF Advisers LLC increased its stake in Sanofi by 31.8% during the 4th quarter. DCF Advisers LLC now owns 14,500 shares of the company’s stock worth $699,000 after buying an additional 3,500 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on SNY shares. The Goldman Sachs Group initiated coverage on Sanofi in a research report on Friday. They issued a “neutral” rating and a $65.00 target price on the stock. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Stock Down 1.5 %

Shares of NASDAQ:SNY opened at $56.90 on Friday. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12. The stock has a market cap of $144.40 billion, a P/E ratio of 22.85, a PEG ratio of 1.01 and a beta of 0.58. The business has a fifty day moving average of $54.55 and a two-hundred day moving average of $52.89. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, research analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.